SCHEMBL624431

SCHEMBL624431

COc1cncc(-c2cn3nc(NC4CCN(S(C)(=O)=O)CC4)sc3n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 2/20 0.48
DYRK1A Q13627 1/20 0.45
PIK3R1 P27986 1/20 0.41
PIK3CA P42336 1/20 0.41
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
PTK2 Q05397 1/20 0.40
HPGDS O60760 1/20 0.40
SYK P43405 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
BRAF P15056 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
F2RL3 Q96RI0 3/20 0.38
CDK1 P06493 5/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL626172 0.88 DYRK1A (0.38) FYNDYRK1ACDK1CDK2CCNB2
SCHEMBL625477 0.87 FYN (0.50) FYNPIK3R1PIK3CACA12CA1
SCHEMBL1944169 0.86 FYN (0.53) FYNSYKCA12CA1CA2
SCHEMBL626165 0.85 IDO1 (0.47) F2RL3CDK1CDK2CCNB2CCNE2
SCHEMBL626187 0.85 JAK3 (0.38) FYNDYRK1AJAK3F2RL3CDK1
SCHEMBL625465 0.84 FYN (0.52) FYNDYRK1ASYKCA12CA1
SCHEMBL2253571 0.84 FYN (0.52) FYNSYKBRAFPDE4APDE4B
SCHEMBL623928 0.83 FYN (0.49) FYNDYRK1APDE4BF2RL3CDK1
SCHEMBL624430 0.82 FYN (0.72) FYNPIK3CA
SCHEMBL626207 0.78 MAP3K12 (0.46) PIK3CACDK1CDK2CCNB1CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012020215-A1 AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2012-02-16 WO disclosed